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Abstract
Background: Acute uncomplicated cystitis (AUC) is a common ailment in the urological setting. Guidelines for urinary
tract infections are based on large-scale multi-centre, epidemiological and international studies. The objective of this
observational study was to establish whether the results of a multi-centre study on the resistance profile of Escherichia
coli (E. coli) in patients with AUC could be directly applied to an urological practice in a major European city or whether
there are divergences in the resistance profile.
Methods: An observational study was applied prospectively to 502 patients with AUC between January 2015 and
January 2017). Personal data were anonymised. Exclusion criteria were the patient’s age (<18) and treatment with an
antibiotic in the week preceding examination.
Results: The average age was 32 (range 18–56). The most commonly detected bacteria was E. coli with 86%, followed
by Enterococcus faecalis with 10% and Klebsiella pneumoniae with 4%. Resistance tests showed E. coli to be highly
sensitive to fosfomycin (99.2%), nitrofurantoin (98.1%) and cefpodoxime (92.9%). E. coli exhibited resistance to
ciprofloxacin (CIP) in 15.1%, to trimethoprim/sulfamethoxazole (TRS) in 25.2% and to amoxicillin/clavulanic acid
(AMC) in 34% of cases.
Conclusion: The comparison between data from this study and data from a multi-centre European (ECO-SENSI,
ECO-SENSII and the 2014 update) showed relatively good sensitivity rates for fosfomycin and nitrofurantoin but
significant differences in respect of resistance levels to TRS, CIP and AMC. AUC should therefore only be treated
with TRS, CIP and AMC after a susceptibility test has been carried out.
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Background
Uncomplicated acute cystitis is among the most common
ailments presented in urological practice. Over recent
years the causative bacteria have remained much the
same. Escherichia coli (E. coli) is still by far the most com-
mon uropathogen for acute uncomplicated cystitis (AUC)
in women and is found in more than 80% of the positive
urine cultures [1]. In practice, the condition is generally
treated empirically on the basis of epidemiological studies
and resistance testing, although antibiotic treatment is be-
coming increasingly complex. This is due to the con-
stantly deteriorating resistance profile of E. coli strains.
This study therefore aimed to determine whether the
current recommendations issued by European epidemio-
logical studies [2–6] are directly applicable to a specialist
urological practice in a European city and whether the
empirical therapy may require adjustment.* Correspondence: mseitz@me.com1UroClinic München GbR – Campus Bogenhausen, Richard-Strauss-Strasse 82,
81679 Munich, Germany
2Department of Urology, Ludwig-Maximilians-University of Munich,
Marchioninistr. 15, 81377 Munich, Germany
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Seitz et al. BMC Infectious Diseases  (2017) 17:685 
DOI 10.1186/s12879-017-2789-7
Methods
This prospective study was carried out in a urological
practice in a major European city (Munich). From January
2015 to January 2017 a consecutive group of 502 patients
with AUC were included in the observational study. Indi-
cators of an AUC were defined in terms of at least one of
the following symptoms: suprapubic pain, urge symptoms,
dysuria and increased voiding frequency.
Exclusion criteria were if the patient was under the
age of 18 or had taken antibiotics during the 7 days prior
to examination. The examination medium was a clean
catch mid-stream urine sample from the patient. Urine
was cultured in the institute’s own laboratory (Instand®
certified). This included the identification of the bacteria
and resistance testing in accordance with EUCAST cri-
teria. A urine culture was defined as positive if
≥10e3CFU/mL. Mixed cultures were not analysed.
The principles of Section 15 of the Bavarian Rules of
Professional Conduct were observed. Consultations were
held with the ethics commission of the Bavarian State
Chamber of Physicians prior to beginning the study. A
separate ethics application was not necessary as the pur-
pose of the research project was quality assurance and
imposed neither additional burdens nor examinations on
patients and involved no personal data. The criteria of
the Declaration of Helsinki were observed. Patients were
informed about the project and required to consent in
writing. Patients’ data was anonymised once the micro-
biological results had become available.
Results
The average age of the patients was 32.7 years (range
18–65). The age peak in the cohort was between ages 18
and 25 (42%). The distribution of urinary tract infections
was found to be more common in the age group of 18–
25 with 42% and decreased with age to 8–8.2% in
women aged 46–65 years. Among pre-menopausal pa-
tients AUC was more common than among post-
menopausal women (86.9% vs. 13.1%). Three main fac-
tors that might influence the rate of AUC in our cohort
were recurrent urinary tract infections (20.3%), preced-
ing sexual intercourse (15.3%) and a new sex partner
(12.9%). Patient characteristics are shown in Table 1.
After the exclusion of mixed cultures, a total of 423
patients from an initial 502 remained for analysis. The
most common bacteria was E. coli with 86.3% (365/423)
followed by Enterococcus faecalis with 10.2% (43/423)
and Klebsiella pneumoniae with 3.5% (15/423). A cohort
of 365 patients was available for E. coli analysis. Suscep-
tibility testing showed E. coli strains to be highly sensi-
tive to the following oral antibiotics: fosfomycin-
trometamol (99.2%), nitrofurantoin (98.1%) and cefpo-
doxime (92.9%). E. coli was resistant to ciprofloxacin in
15.1% of cases, to trimethoprim/sulfamethoxazole in
25.2% of cases and to amoxicillin/clavulanic acid in
25.2% of cases (Table 2).
Discussion
In this prospective observational study we were able to
raise “real-world” data on causative pathogens of AUC
and their corresponding resistance profiles to antibiotics
in an urological practice. Treatment is usually based on
empirical data collected from multi-centre studies. It is
known that the resistance profiles of causative bacteria
changes over the course of time. Not only are these
changes time-related, they also differ considerably across
regions and nations [3, 5–9]. The question therefore
arises whether guideline recommendations for the use of
specific antibiotics in AUC are directly applicable to an
urological practice in a major German city, or whether
such guideline recommendations require regional and
national modification.
Comparison of our data to international studies
Successful empirical treatment is based on the fact that
an absolute majority of the pathogenic bacteria actually
is susceptible to the selected substance. Unfortunately,
experience has shown that resistance rates constantly
change adversely. For example, the ECO-SENS I Study
(multicentric, European) carried out between 1999 and
2000 and the ECO-SENS II Study (2007–2008) show a
shift in resistence rates of E. coli to antibiotics in Europa
over an 8-year period [5, 6]. A recently published
Table 1 Patient characteristics
Patient characteristics Absolute Percentage
502 100
Age
Age 18–25 211 42.0
Age 26–35 140 27.9
Age 36–45 70 13.9
Age 46–55 40 8.0
Age 56–65 41 8.2
Average age [range] 32.7 [18–
65]
–
Pre-menopause 436 86.9
Post-menopause 66 13.1
Risk factors
Recurrent urinary tract infections 102 20.3
Diabetes mellitus 15 3.0
Pregnancy 4 0.8
New sex partner 65 12.9
First-degree relative with urinary tract
infections
34 6.8
Intercourse-related 77 15.3
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update-2014 of ECO-SENS and simultaneous compari-
son with the ECO-SENS I and II studies gives alarming
resistance rates for France, Germany, Spain, Sweden and
UK with regard to ciprofloxacin (4.8% and 30.8%) and to
trimethoprim (26.9% and 46.0%) [6]. In addision, our
data from this manuscript demonstrate alarming resis-
tence rates for aminopenicillins (ampicillin, amoxicillin
in combination with sulbactam and clavulanic acid, re-
spectively) between 25.2 and 39.7% and therefore differs
significantly from data in ECO-SENS and the 2014-
update (between 4.5 and 28%) [5, 6]. This also applies to
ciprofloxacin, ECO-SENS II gives international resis-
tence rates of 3.9%, whereas our study finds this to be
15.1%. Ultimately, it is apparent that resistance rates
from a European multi-centre study cannot be randomly
applied to a small geographic region in Europe. But on
the basis of our data and international studies (ECO-
SENS) it can currently be confirmed that fosfomycin-
trometamol and nitrofurantoin can be given in our uro-
logical practice as first-line therapy without susceptibility
testing.
Comparison of our data to national/regional data
A comparison of E. coli susceptibility testing reveals that
ECO-SENS I and II contain no data specific to Germany
[5, 7]. With regard to our data, the update-2014 (to the
studies ECO-SENS I and II) published in 2015 only al-
lows comparisons with nitrofurantoin, ciprofloxacin and
amoxicillin/clavulanic acid (fosfomycin was not included
in the mentioned study; we did not test the monother-
apies mecilliam, cefadroxil and trimethoprim in our
study) [6]. In Germany in 2014, resistance rate was
found to be 8.3% for amoxicillin/clavulanic acid, 2.3%
for nitrofurantoin and 20.3% for ciprofloxacin, the corre-
sponding figures in our study were 25.2, 1.9 and 15.1%
respectively. An analysis of the results of the inter-
national ARESC Study (Antimicrobial Resistance Epi-
demiological Survey on Cystitis) on the prevalence and
resistance rates of pathogens that cause AUC, particu-
larly in respect of the figures for Germany and our fig-
ures, show similarly resistence rates for E. coli to
ampicillin 40.8% vs. 39.7%, for cefuroxime 8.7% vs. 9.3%,
for trimethoprim/sulfamethoxazole 26.0% vs. 25.2%, for
nitrofurantoin 4.6% vs. 1.9%, and for fosfomycin 2.1% vs.
0.8%. Significant inconsistencies are found for ciproflox-
acin (ARESC 4.6% vs. 15.1%) and amoxicillin/clavulanic
acid (ARESC 11.2% vs. 25.2%) [8]. A comparison of our
data with the german-wide data shows a pleasant
consistency with regard to susceptibility testing for E.
coli particularly in respect of the antibiotics from the
german and european guideline recommendations (fos-
fomycin and nitrofurantoin) [10]. Our data allows the
conclusion that, if treatment with guideline-compliant
fosfomycin and nitrofurantoin is not intended, cipro-
floxacin, trimethoprim/sulfamethoxazole and especially
aminopenicillins should only be prescribed after sus-
ceptibility testing.
The reasons for the relative high rate of resistances to
ciprofloxacin and amoxicillin/clavulanic acid found in
our study is a matter of speculation. A possible reason
for an increased resistance situation could be the loca-
tion of the urological practice in a metropolitan area
with its high-density healthcare system and associated
high rate of prescription of antibiotics (CIP and AMC).
Such antibiotics are not only prescribed for urinary tract
infections but also for numerous other medical condi-
tions. On the other hand, there is no plausible explan-
ation for the constantly high level of sensitivity to
fosfomycin. It could be equally due to doctors’ restrictive
prescription practice and the narrow range of indications
for fosfomycin approval. In contrast, a study by Oreo et
al. showed that the broader use of fosfomycin in parts of
Spain has already caused an increase in resistance rates
[11].
The strength of the study lies in its collection of real-
world data from a relatively high number of patients in
everyday situations in an urological practice. To our
knowledge, this is the first publication comparing data
from a large cohort in a single centre with national and
international multi-centric data. At the same time, the
Table 2 Percentage susceptibility of E. coli isolated from
women with AUC
Antibiotic Susceptibility of the antibiotic to E. coli
[in %]
Ampicillin 60.3
Ampicillin/sulbactam 65.5
Amoxicillin 69.6
Amoxicillin/clavulanic acid 74.8
Piperacillin 69.6
Piperacillin/tazobactam 91.8
Cefuroxime 90.7
Cefpodoxime 92.9
Cefotaxime 95.6
Ceftazidime 95.3
Imipenem 100
Meropenem 100
Ciprofloxacin 84.9
Levofloxacin 86.3
Moxifloxacin 86.0
Gentamycin 94.0
Tetracycline 74.8
Nitrofurantoin 98.1
Trimethoprim/sulfamethoxazole 74.8
Fosfomycin-trometamol 99.2
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strength of the study is also its weak point. The pro-
spective, single-centre study design does not permit con-
clusions to be drawn for other parts of the country or
Europe, which is absolutely not the study aim. A further
disadvantage of the study design could be the 2-year
period required to recruit patients. This constitutes a
possible bias, as the resistance situation during recruit-
ment could have changed or deteriorated. This, however,
does not affect the study findings in general.
In respect of the international and national differences
in the resistance profile, for the future it needs to be dis-
cussed whether large laboratories in the healthcare sys-
tem should regularly collect data on the resistance
profile of uropathogenic bacteria at national and/or re-
gional level. This could ensure that, in future, empirical
AUC therapy can also be initiated without requiring a
urine culture and susceptibility testing in each individual
case. In the update to the EAU (European Association of
Urology) guidelines from March 2015, fosfomycin, piv-
mecilliam and nitrofurantoin are considered to be first-
line therapy [12] with high levels of evidence (LE: 1a,
GR: A). In particular fosfomycin exhibits a high level of
susceptibility to ESBL-producing E. coli, which is already
on the decline on some regions of Spain. Furthermore,
resistance rates of <20% already suffice to class an anti-
biotic as first-line medication [13, 14]. This definition
renders empirical treatment with aminopenicillins with
or without sulbactam or clavulanic acid impossible in
our (regional) practice, whereas aminopenicillins could
still be used at national level. In this respect, with a re-
sistance rate of 15.1% for ciprofloxacin, it would only be
a question of time before empirical therapy with this
agent at regional level would no longer make sense.
Conclusions
Despite the evidence for international and national differ-
ences in the resistance profile of E. coli to antibiotics, the
guidelines can still be applied to empirical treatment of
AUC. As significant changes may still occur in regional
susceptibility to recommended alternative antibiotics such
as ciprofloxacin, aminopenicillins and trimethoprim/sulfa-
methoxazole, a urine culture with subsequent susceptibil-
ity test should be performed before use. Ongoing regular
monitoring of the resistance profile at international, na-
tional and regional levels could increase the understanding
of and reduce reaction times to the development of
resistances.
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